43.04 USD
▼-1.80-4.01%
盘后 44.53 +3.46%
2026-09-15
市值
$1.37B
市盈率
—
EPS
-3.81
股息率
—
52 周区间
13.36 – 50.16
成交量
320.55K
Beta
—
目标价
53.38
52W 低 13.3652W 高 50.16
价格走势
公司简介
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ...